Portola Pharmaceuticals, Inc.
Overview
Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics in the areas of thrombosis and other hematologic conditions. It is a subsidiary of Alexion, AstraZeneca Rare Disease, which acquired Portola in 2020.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Portola Pharmaceuticals, Inc. in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this Portola Pharmaceuticals, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.